Loading clinical trials...
Loading clinical trials...
An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies (DLB)
Conditions
Interventions
neflamapimod
Locations
2
France
Hôpital Lariboisière - APHP; Centre de Neurologie Cognitive
Paris, France
Strasbourg University Hospital (Les Hopitaux Universitaires de Strasbourg)
Strasbourg, France
Start Date
October 16, 2024
Primary Completion Date
March 11, 2026
Completion Date
March 25, 2026
Last Updated
April 8, 2026
NCT07314190
NCT01278407
NCT04055532
NCT00598650
Lead Sponsor
EIP Pharma Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions